JAK2-IN-13

• Description:

  JAK2-IN-13 is a potent and orally active JAK2 inhibitor with an IC50 of 54.7 nM. JAK2-IN-13 downregulates the expressions of p-STAT3 and p-STAT5. JAK2-IN-13 exhibits good bioavailability and potent inhibition of rhEPO-induced extramedullary erythropoiesis and polycythemia vera. JAK2-IN-13 can be used for the study of myeloproliferative neoplasms[1].

• UNSPSC:

  12352005

• Target:

  JAK; STAT

• Related Pathways:

  Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Smiles:

  CC1=CN=C(NC(C=C2)=CC3=C2OCCN4CCCC4)N=C1NC5=CC(Cl)=CC(COC3)=C5

• Molecular Formula:

  C25H28ClN5O2

• Molecular Weight:

  465.98

• References & Citations:

  [1]Mei W, et al. Design, Synthesis, and Biological Evaluation of Macrocyclic 2-Amino-4-phenylaminopyrimidine Derivatives as Potent JAK2 Inhibitors. J Med Chem. 2025 Jul 10;68 (13) :13822-13835.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  JAK2; STAT3; STAT5